The U.S. Food and Drug Administration approved the pill for weight loss earlier this month, intensifying Lilly's competition with rival Novo Nordisk.

The trial of 2,700 patients with increased cardiovascular risk showed that Foundayo lowered ‌the risk of heart attack, stroke ...

Under the new priority voucher program (CNPV), the FDA has approved a new oral GLP-1 drug, Foundayo, offering an alternative ...

The new Wegovy 7.2mg single-dose pen means one semaglutide injection replaces three for eligible obesity patients in the UK ...

"Lilly debuts more Foundayo data as FDA requests post-marketing trials" was originally created and published by ...

Many people who take GLP-1 medications pay for them completely out of pocket—including about a quarter of people with health ...

The Food and Drug Administration is asking Eli Lilly to gather more safety data on its new weight loss pill, Foundayo, ...

The FDA loosening and rollback of the Category 2 classification is a direct unlock for Hims’ peptide expansion, including its ...

The difference between how Wegovy and Zepound work matters when it comes to their efficacy. According to Dr. Dovec, ...

The FDA also asked Lilly to conduct a milk-only lactation study in women who have received a dose to assess concentrations of ...

At the heart of the request is whether taking Foundayo - made with a new active ingredient called orforglipron - could be ...

Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, is partnering with OpenAI to deploy the technology ...